Avacta Therapeutics received FDA IND clearance for AVA‑6103, a tumor‑activated precision peptide‑drug conjugate targeting FAP, clearing the way for first‑in‑human studies in solid tumors. Separately, Neok Bio obtained IND clearance for its bispecific ADC NEOK‑001 and plans to initiate a phase I trial in the coming months. Both clearances reflect continued regulatory receptivity to next‑generation targeted payloads and will deliver early clinical proof‑of‑concept readouts next year.